OXIGENE, INC. DEF 14A

Company

Oncotelic Therapeutics, Inc.

Filed

May 19, 2005

Period of Report

July 7, 2005

Accession Number

0000950135-05-002966

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →